Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Health Status
  • Kidney Neoplasms
  • Pyrimidines
  • Quality of Life
  • Sulfonamides

abstract

  • Results support the favourable benefit-risk profile of pazopanib and suggest patients experiencing tumour response/stabilisation also may have better HRQoL compared to those without this response.

publication date

  • February 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2011.05.017

PubMed ID

  • 21689927

Additional Document Info

start page

  • 311

end page

  • 23

volume

  • 48

number

  • 3